Govt dismisses concerns over Inflectra substitution

The federal government has dismissed concerns over pharmacy-level substitution of infliximab biosimilar Inflectra in a letter to prescribers.

Deputy department of health secretary Andrew Stuart says patients may be offered either the original brand Remicade or its biosimilar Inflectra at the time of dispensing.

Pharmacists have to consult with patients before any substitution occurs, he